Bartlett & Co’s Haemonetics HAE Stock Holding History

Bartlett & Co’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-103	Closed	-$4K	–	753
2014 Q4	$4K	Buy	+103	New	+$3.77K	﹤0.01%	708

Other funds holding HAE

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bartlett & Co's HAE Position: Q1 2015 in Review

Bartlett & Co sold out of Haemonetics (HAE) in Q1 2015, closing a stake of 103 shares — an estimated $4K sold.

Bartlett & Co first reported a position in HAE in Q4 2014 and held it in 1 quarter. The position peaked at $4K in Q4 2014. 169 funds tracked by Wall St. Rank hold HAE as of Q1 2015.

Bartlett & Co reported no remaining Haemonetics position as of Q1 2015 after selling out during the quarter.
Bartlett & Co sold 103 Haemonetics shares in Q1 2015, an estimated $4K.
Bartlett & Co first reported a position in Haemonetics in Q4 2014 and held it in 1 quarter.
Bartlett & Co's Haemonetics position peaked at $4K in Q4 2014.
169 funds tracked by Wall St. Rank held Haemonetics as of Q1 2015.

Based on Bartlett & Co's 13F filing for Q1 2015, filed 1 May 2015.